_
PV is a life-threatening condition associated with increased mortality and reduced quality of life1,2
PV is a myeloproliferative neoplasm characterised by an increase in blood cell production.1,2 A mutation in the JAK2 gene leads to an overactive JAK/STAT pathway.1 The result is an elevated HCT value and increased risk of thromboembolic events and debilitating symptoms.2,3
In the UK, 2 people per 100,000 have PV4
Of patients with PV have a JAK2 mutation1
Median overall survival*1
Median age at diagnosis5
Patients with PV have a high symptom burden that detrimentally impacts their lives1,2
Patients with PV may suffer from a wide range of symptoms that can impact their quality of life.2,6
Click each symptom to see how many patients with PV (n=538) reported being affected by it:†6
discomfort
problems
61% of patients report symptom reduction as their primary goal of treatment‡2
Patients can still be burdened by symptoms despite blood count control6
The prospective, observational REVEAL study of 1813 patients with PV showed that a moderately high symptom burden is present regardless of blood count control.7
Patients may not understand that any changes to how they are feeling, even while their blood counts are controlled, may be related to their PV. They can regularly track their symptoms using an online tracker to ensure they give you the full picture during each appointment.
Help patients monitor their symptoms with the Novartis-funded MPN10 tracker – download here or copy and paste the link into your browser: https://www.mpntracker.com/en-GB
Discover more information about PV and how it impacts the people who live with it:
Hydroxyurea is synonymous with/refers to hydroxycarbamide throughout.
*Among 826 Mayo Clinic patients with ET, PV or PMF, the respective median survivals were approximately 20 years for ET, 14 years for PV and 6 years for PMF1
†Data from self-reported symptom scores from patients with PV (n=538) in a study evaluating the MPN-SAF TSS tool (N=1433).6 The MPN-SAF TSS is calculated as the mean score for the 10 items shown here. Self-reported symptom severity was rated on a 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) scale. In this study, the MPN-SAF TSS for PV was calculated as mean 21.8 (SD 16.3).6
‡Data from patients with MPNs (ET, n=302; MF, n=174; PV, n=223) surveyed in the International MPN Landmark Survey (N=699).2
ET, essential thrombocythaemia; HCT, haematocrit; HU, hydroxyurea; MF, myelofibrosis; MPN, myeloproliferative neoplasm; MPN-SAF TSS, Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score; PMF, primary myelofibrosis; PV, polycythaemia vera; SD, standard deviation.
References
- Tefferi A, Barbui T. Am J Hematol. 2020;95:1599–1613.
- Harrison CN, et al. Ann Hematol. 2017;96:1653–1665.
- Tefferi A, et al. Leukemia. 2021; 35:3339–3351.
- MPN Voice. Polycythaemia Vera. Available at: https://www.mpnvoice.org.uk/about-mpns/questions/polycythaemia-vera/. Last accessed July 2023.
- Lurlo A, et al. Int J Mol Sci. 2020;21:5805.
- Emanuel RM, et al. J Clin Oncol. 2012;30:4098–4041.
- Grunwald MR, et al. Clin Lymphoma Myeloma Leuk. 2019;19:579–584.